Company Filing History:
Years Active: 2010-2015
Title: The Innovations of Yu-Hui Cheng: A Pioneer in Pharmaceutical Delivery Systems
Introduction
Yu-Hui Cheng, a notable inventor based in Nottingham, GB, has made significant contributions to the field of pharmaceutical sciences. With a total of six patents to her name, she has focused her innovative efforts on enhancing drug delivery systems, particularly targeting intranasal applications.
Latest Patents
Among her latest patents, Cheng has developed a non-aqueous pharmaceutical composition designed for the intranasal delivery of drugs. This groundbreaking composition includes two primary components: (i) the drug itself and (ii) a non-aqueous vehicle that features propylene glycol combined with at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, and dimethyl sulfoxide. Notably, the formulation specifies that the vehicle may comprise 40 to 100% by volume of either N-methylpyrrolidone or dimethyl sulfoxide (DMSO). Additionally, her innovations extend to pharmaceutical powder compositions for intranasal delivery, incorporating benzodiazepine drugs alongside chitosan or its derivatives.
Career Highlights
Cheng's work at Archimedes Development Limited has positioned her as a leader in pharmaceutical innovation. Her research and inventive spirit have paved the way for advancements that could potentially transform how medications are administered, offering more effective delivery methods.
Collaborations
Throughout her career, Yu-Hui Cheng has collaborated with talented colleagues, including Peter James Watts and Alan Smith. These partnerships have not only enriched her research but also facilitated the sharing of diverse ideas and expertise within the realm of pharmaceutical sciences.
Conclusion
In summary, Yu-Hui Cheng stands out as an influential inventor dedicated to improving drug delivery systems. Her impressive portfolio of patents demonstrates her commitment to innovation and her potential to make lasting impacts on the pharmaceutical industry. As she continues her work at Archimedes Development Limited, the medical community eagerly anticipates her future contributions.